PIK3CG and neoplasm: A likely explanation is that currently available pan-PI3K inhibitors are not tolerated at doses that completely inhibit PI3K activity, or that the pharmacokinetics are insufficient to maintain complete suppression of all PI3K isoforms in NK cells over the time course of tumor rejection models.